# Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

> **NCT06975878** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Sanofi** · enrollment: 1092 (actual)

## Conditions studied

- Pneumococcal Immunization
- Healthy Volunteers

## Interventions

- **BIOLOGICAL:** PCV21 vaccine
- **BIOLOGICAL:** Vaxneuvance vaccine
- **BIOLOGICAL:** Hexyon vaccine
- **BIOLOGICAL:** M-M-RvaxPro vaccine
- **BIOLOGICAL:** Varivax vaccine

## Key facts

- **NCT ID:** NCT06975878
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-05-22
- **Primary completion:** 2027-08-25
- **Final completion:** 2027-08-25
- **Target enrollment:** 1092 (ACTUAL)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06975878

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06975878, "Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT06975878. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*